Printer Friendly

NX Prenatal to Present Preeclampsia Biomarker Risk Assessment Data at 2018 Society of Reproductive Investigation Annual Meeting.

M2 PHARMA-February 21, 2018-NX Prenatal to Present Preeclampsia Biomarker Risk Assessment Data at 2018 Society of Reproductive Investigation Annual Meeting

(C)2018 M2 COMMUNICATIONS

- US-based women's healthcare molecular diagnostic company NX Prenatal Inc. will present new clinical study data at the Society of Reproductive Investigation's 65th annual scientific meeting in San Diego, California, on March 9th, 2018, the company said.

The oral presentation will describe results from a study of plasma samples obtained from pregnant mothers demonstrating proteomic biomarkers that are already unique in their expression profiles at 10-12 weeks gestation among women who go on to experience preeclampsia.

The new study builds upon a series of previously published studies in which NX Prenatal has demonstrated that the enrichment of exosome and microvesicle particles from maternal blood and subsequent proteomic analysis enables risk stratification of spontaneous preterm birth in the first trimester of pregnancy.

Privately held NX Prenatal is a molecular diagnostics company. The company's NeXosome technology harvests biologically active and stable microparticles, such as exosomes, from the maternal bloodstream, to provide a real-time and non-invasive view of changing maternal and fetal tissues.

This technology is enabling the development of a series of early warning blood tests for pregnancies that may result in a variety of adverse outcomes, such as spontaneous preterm birth and preeclampsia.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2018 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Feb 21, 2018
Words:226
Previous Article:Alira Health acquires Clinical Assistance Programmes for undisclosed amount.
Next Article:Imfinzi (durvalumab) Approved for Treatment of Unresectable Stage III NSCLC by US FDA.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters